Grant ID

97-RC-299-1

Illness

Bipolar Disorder

Primary Drug/Intervention

S-adenosyl-methionine (SAMe)

Primary Dosage

1600 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Cohen

Sample Size

15

Duration of Study Period for Each Subject

4 weeks

Outcome Measurements

Pharmacokinetic parameters

Results

Sixteen normal control subjects received s-adenosyl methionine (up to 1600 mg per day) for four weeks. Treatment was not associated with increased serum levels of toxic methylated compounds such as methanol, formic acid, or formaldehyde. Homocysteine levels were also measured and did not increase with treatment. Treatment was generally well-tolerated, although one patient experienced a mixed manic mood episode.

Publication

Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-Adenosyl-L-methioine (SAMe) in humans. Pharmacotherapy. 24 (1): 1501-1507, 2004.

Link

http://www.ncbi.nlm.nih.gov/pubmed/15537554

PI Name

Bruce Cohen

Degree

MD

Center

N/A

Institution

N/A

Address

City or Town

Bemont

State or Province

MA

Zip or Postal Code

N/A

Country

USA

Email Address

cohenb@mclean.harvard.edu